OBJECTIVE: This study used childhood cancer survivors as a novel model to study whether children who experience central nervous system (CNS) injury are at higher risk for neurocognitive impairment associated with subsequent late onset chronic health conditions (CHCs). METHODS: Adult survivors of childhood cancer (n = 2,859, ≥10 years from diagnosis, ≥18 years old) completed a comprehensive neurocognitive battery and clinical examination. Neurocognitive impairment was defined as age-adjusted z score < 10th percentile. Participants impaired on ≥3 tests had global impairment. CHCs were graded using the Common Terminology Criteria for Adverse Events v4.3 (grade 1, mild; 2, moderate; 3, severe/disabling; 4, life-threatening) and were combined into a severity/burden score by frequency and grade (none/low, medium, high, and very high). A total of 1,598 survivors received CNS-directed therapy including cranial radiation, intrathecal methotrexate, or neurosurgery. Logistic regression estimated the odds of neurocognitive impairment associated with severity/burden score and grade 2 to 4 conditions, stratified by CNS treatment. RESULTS: CNS-treated survivors performed worse than non-CNS-treated survivors on all neurocognitive tests and were more likely to have global neurocognitive impairment (46.9% vs 35.3%, p < 0.001). After adjusting for demographic and treatment factors, there was a dose-response association between severity/burden score and global neurocognitive impairment, but only among CNS-treated survivors (high odds ratio [OR] = 2.24, 95% confidence interval [CI] = 1.42-3.53; very high OR = 4.07, 95% CI = 2.30-7.17). Cardiovascular and pulmonary conditions were associated with processing speed, executive function, and memory impairments in CNS-treated but not non-CNS-treated survivors who were impacted by neurologic conditions. INTERPRETATION: Reduced cognitive/brain reserve associated with CNS-directed therapy during childhood may make survivors vulnerable to adverse cognitive effects of cardiopulmonary conditions during adulthood. ANN NEUROL 2021;89:534-545.
OBJECTIVE: This study used childhood cancer survivors as a novel model to study whether children who experience central nervous system (CNS) injury are at higher risk for neurocognitive impairment associated with subsequent late onset chronic health conditions (CHCs). METHODS: Adult survivors of childhood cancer (n = 2,859, ≥10 years from diagnosis, ≥18 years old) completed a comprehensive neurocognitive battery and clinical examination. Neurocognitive impairment was defined as age-adjusted z score < 10th percentile. Participants impaired on ≥3 tests had global impairment. CHCs were graded using the Common Terminology Criteria for Adverse Events v4.3 (grade 1, mild; 2, moderate; 3, severe/disabling; 4, life-threatening) and were combined into a severity/burden score by frequency and grade (none/low, medium, high, and very high). A total of 1,598 survivors received CNS-directed therapy including cranial radiation, intrathecal methotrexate, or neurosurgery. Logistic regression estimated the odds of neurocognitive impairment associated with severity/burden score and grade 2 to 4 conditions, stratified by CNS treatment. RESULTS: CNS-treated survivors performed worse than non-CNS-treated survivors on all neurocognitive tests and were more likely to have global neurocognitive impairment (46.9% vs 35.3%, p < 0.001). After adjusting for demographic and treatment factors, there was a dose-response association between severity/burden score and global neurocognitive impairment, but only among CNS-treated survivors (high odds ratio [OR] = 2.24, 95% confidence interval [CI] = 1.42-3.53; very high OR = 4.07, 95% CI = 2.30-7.17). Cardiovascular and pulmonary conditions were associated with processing speed, executive function, and memory impairments in CNS-treated but not non-CNS-treated survivors who were impacted by neurologic conditions. INTERPRETATION: Reduced cognitive/brain reserve associated with CNS-directed therapy during childhood may make survivors vulnerable to adverse cognitive effects of cardiopulmonary conditions during adulthood. ANN NEUROL 2021;89:534-545.
Authors: Melissa M Hudson; Kirsten K Ness; Vikki G Nolan; Gregory T Armstrong; Daniel M Green; E Brannon Morris; Sheri L Spunt; Monika L Metzger; Kevin R Krull; James L Klosky; Deo Kumar Srivastava; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2010-12-15 Impact factor: 3.167
Authors: Eric J Chow; Yan Chen; Melissa M Hudson; Elizabeth A M Feijen; Leontien C Kremer; William L Border; Daniel M Green; Lillian R Meacham; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Cécile M Ronckers; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Irma W E M van Dijk; Flora E van Leeuwen; Rita E Weathers; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui Journal: J Clin Oncol Date: 2017-11-02 Impact factor: 44.544
Authors: Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Lancet Date: 2017-09-08 Impact factor: 79.321
Authors: AnnaLynn M Williams; Sedigheh Mirzaei Salehabadi; Mengqi Xing; Nicholas S Phillips; Matthew J Ehrhardt; Rebecca Howell; Yutaka Yasui; Kevin C Oeffinger; Todd Gibson; Eric J Chow; Wendy Leisenring; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Liwen Peng; Lok Sum Yang; Perri Yam; Chun Sing Lam; Agnes Sui-Yin Chan; Chi Kong Li; Yin Ting Cheung Journal: Front Oncol Date: 2021-04-20 Impact factor: 6.244
Authors: AnnaLynn M Williams; Kevin R Krull; Carrie R Howell; Pia Banerjee; Tara M Brinkman; Sue C Kaste; Robyn E Partin; Deokumar Srivastava; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: J Clin Oncol Date: 2021-07-20 Impact factor: 44.544